✦ LIBER ✦

ChemInform Abstract: Management Guidelines for the Use of Alemtuzumab in Chronic Lymphocytic Leukemia

✍ Scribed by A. Oesterborg; R. Foa; R. F. Bezares; C. Dearden; M. J. S. Dyer; C. Geisler; T. S. Lin; M. Montillo; M. H. J. van Oers; C.-M. Wendtner; et al. et al.

Publisher: John Wiley and Sons
Year: 2010
Weight: 15 KB
Volume: 41
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.201043262

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Routine clinical use of alemtuzumab in p

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia : A nation-wide retrospective study in Austria

✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono

Guidelines for clinical protocols for ch

Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

✍ Dr. Bruce D. Cheson; John M. Bennett; Kanti R. Rai; Michael R. Grever; Neil E. K 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 866 KB

Alemtuzumab by continuous intravenous in

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Erratum: Alemtuzumab by continuous intra

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

What is the current evidence for antigen

What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?

✍ Gerard Tobin; Anders Rosén; Richard Rosenquist 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

For many years it has been evident that B-cell chronic lymphocytic leukemia (CLL) displays preferential usage of individual immunoglobulin (Ig) variable heavy chain (V(H)) genes. The V(H)1-69 gene was the first to be reported overrepresented in a large number of CLL patients, where the V(H)1-69(+) C

The management of chronic lymphocytic le

The management of chronic lymphocytic leukemia at a single centre over a 24-year period: prognostic factors for survival

✍ T. Karmiris; Dr. A. Z. S. Rohatiner; S. Love; M. Carter; R. K. Ganjoo; J. Amess; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 592 KB

## Abstract Over a 24‐year period, 137 patients were referred for management of newly diagnosed chronic lymphocytic leukemia. One hundred and nineteen patients have been reviewed in terms of response to therapy and prognostic factors for survival; 18 patients were excluded either because lymph node